Meridian Medical Technologies, LLC, and the European Commission’s DG HERA Sign Agreement for 13 Countries From the EEA to Purchase Tecovirimat SIGA
“Time is of the essence during medical emergencies, as we saw in 2022 when EU member states required emergency shipments of Tecovirimat SIGA to treat patients infected with mpox,” said Meridian Medical Technologgies Commercial Head – Injectables & Health Security, Tom Handel. “This joint procurement framework contract, a significant milestone for both Meridian and HERA, reduces the time and effort required to put individual contracts in place with each member state from months to days. There are now multiple paths in Europe for streamlined procurement, allowing member state agencies to get much needed medical countermeasures into the hands of those in need.”